A61K 47/6949
Inclusion complexes
Official title: {inclusion complexes, e.g. clathrates, cavitates or fullerenes}
A61K47/6949 (Inclusion complexes) appears on 1,152 US grants and 1,668 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,152
- Published applications
- 1,668
- Assignees
- 877
- Inventors
- 3,390
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 2 | 0 |
| 1981 | 1 | 0 |
| 1982 | 2 | 0 |
| 1983 | 3 | 0 |
| 1984 | 9 | 0 |
| 1985 | 6 | 0 |
| 1986 | 9 | 0 |
| 1987 | 5 | 0 |
| 1988 | 8 | 0 |
| 1989 | 11 | 0 |
| 1990 | 4 | 0 |
| 1991 | 18 | 0 |
| 1992 | 12 | 0 |
| 1993 | 20 | 0 |
| 1994 | 17 | 0 |
| 1995 | 17 | 0 |
| 1996 | 24 | 0 |
| 1997 | 38 | 0 |
| 1998 | 38 | 0 |
| 1999 | 25 | 0 |
| 2000 | 13 | 0 |
| 2001 | 25 | 7 |
| 2002 | 22 | 33 |
| 2003 | 22 | 50 |
| 2004 | 18 | 61 |
| 2005 | 25 | 66 |
| 2006 | 27 | 38 |
| 2007 | 18 | 64 |
| 2008 | 13 | 50 |
| 2009 | 22 | 47 |
| 2010 | 24 | 75 |
| 2011 | 24 | 63 |
| 2012 | 32 | 57 |
| 2013 | 51 | 67 |
| 2014 | 39 | 57 |
| 2015 | 24 | 68 |
| 2016 | 36 | 71 |
| 2017 | 45 | 65 |
| 2018 | 39 | 83 |
| 2019 | 58 | 74 |
| 2020 | 60 | 95 |
| 2021 | 54 | 102 |
| 2022 | 44 | 84 |
| 2023 | 46 | 69 |
| 2024 | 31 | 92 |
| 2025 | 48 | 79 |
| 2026 | 20 | 51 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Nootropic fullerenes and use22 Sep 2026US 12,741,033 B2Carbon 60 (Zhejiang) Pharmaceutical Technology Co., Ltd.
- Delivery of cyclic compound by using carrier25 Aug 2026US 12,714,754 B2The University of Tokyo
- Compositions of complexing agents26 May 2026US 12,636,265 B2Bexson Biomedical, Inc.
- Cannabinoid chewing gum with sugar alcohols19 May 2026US 12,629,332 B2NordicCan A/S
- Formulations and dosages for administering a compound that inhibits MCL1 protein12 May 2026US 12,622,918 B2Amgen Inc.
- Pharmaceutical compositions comprising meloxicam8 Oct 2026US 2026/0306635 A1Axsome Therapeutics, Inc.
- Biologically compatible, biofilm disrupting composition and methods1 Oct 2026US 2026/0294861 A1
- Pharmaceutical formulation comprising lanosterol, derivative thereof, and cyclodextrin1 Oct 2026US 2026/0295073 A1Carboexpert Inc.
- Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery24 Sep 2026US 2026/0284223 A1Oculis Operations Sàrl
- Aminosterol compounds, aminosterol-cyclodextrin formulations, and methods of using the same10 Sep 2026US 2026/0263485 A1Enterin, Inc.
Most cited
By later US patents
- Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof419US 5,134,127 AUniversity of Kansas · 1992
- Pharmaceutical preparations containing cyclodextrin derivatives406US 4,727,064 AThe United States of America as represented by the Department of Health and Human Services · 1988
- Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof346US 5,376,645 AUniversity of Kansas · 1994
- Cyclodextrin polymers for carrying and releasing drugs324US 6,048,736 A2000
- Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations234US 6,046,177 ACydex, Inc. · 2000